CTOs on the Move


 
Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.pieris.com
  • 255 State Street 9th floor
    Boston, MA USA 02109
  • Phone: 857.246.8998

Executives

Name Title Contact Details

Funding

Pieris raised $50.6M on 02/20/2018
Pieris raised $32M on 11/10/2019
Pieris raised $17.3M on 06/25/2021
Pieris raised $25M on 07/05/2021

Similar Companies

Manhattan Research

Manhattan Research is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ascensia Diabetes Care

Our goal is to provide products and solutions that make a positive, daily difference for people with diabetes. We want to make sure diabetes doesnt get in the way of peoples future, enabling them to live richer lives. At Ascensia Diabetes Care we ...

Innovative Health

HEALTHCARE NEEDS NEW ANSWERS Hospitals in the US are financially fragile and the pandemic has brought many to the verge of bankruptcy. Meanwhile, advancements in pharmaceuticals and medical technology carry the promise of better patient care – a...

Aspen Pharmacare Canada

We have a proud heritage dating back more than 160 years and is committed to sustaining life and promoting healthcare through increasing access to our high quality, affordable medicines and products. As a leading global player in specialty, branded and generic pharmaceuticals, we have an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. We continue to increase the number of lives benefiting from our products that reach more than 150 countries. In line with the our commercial, production and territorial strategies, we have identified Thrombosis, Anaesthetics, High Potency & Cytotoxics as our focused therapeutic categories that will receive our highest focus based on materiality and future potential.